Search academic texts

Information × Registration Number 0215U000356, 0113U003166 , R & D reports Title Establishing the new risk factors and investigating their role for stratification of treatment strategy in different stages of multiple myeloma popup.stage_title Head Maslyak Zvenyslava V., Registration Date 10-02-2015 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 The results of investigations performed in 42 patients with multiple myeloma (MM) and 2 - with acute plazmoblastic leukemia (APL) aged from 38 to 77 years are presented. In 22 of the patients treatment with proteasome inhibitor bortezomib either as monotherapy, or in combination with dexamethasone (VD) or cytotoxic drugs (VCD, VTD, VBD, PAD) was performed. Immunomodulatory drug thalidomide was also used in 22 patients with MM in combination with dexamethasone (TD), melphalan and prednisone (MPT) or within the modified CTD scheme. In 22 of the MM patients the analysis of associative links between metabolic disorders and impairment of hemostasis was performed for further study of prognostic markers of hemostatic complications. Product Description popup.authors Виговська Ольга Ярославівна Виговська Ярослава Іллівна Гуменний Олександр Дмитрович Даниш Ольга Йосипівна Дзісь Іван Євгенович Лещук Остап Васильович Лук'янова Анна Сергіївна Лукавецький Лесь Миронович Мельник Марія Іллярівна Пеленьо Наталія Володимирівна Цяпка Орест Миколайович popup.nrat_date 2020-04-02 Close